NetworkNewsWire Announces Publication Discussing Companies Developing Novel Methods of Extracting Medicinal-Grade Cannabinoids
(firmenpresse) - NEW YORK, NY -- (Marketwired) -- 11/01/17 -- ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids.
The publication, titled, "Economic Impact of Biosynthesis on the Cannabis Industry," highlights biotech companies creating cannabis-based products to treat various medical disorders through the development of high-tech extraction methods.
To view the full publication, visit:
"CBD is just one compound out of more than 90 found within the cannabis plant, though. While many companies with an interest in medicinal marijuana pursue various avenues to extract cannabinoids, (CSE: IN) (OTCQB: IMLFF) has developed a proprietary process capable of extracting all 90+ cannabinoids in a laboratory setting, eliminating most of the costly requirements that typically come with cannabinoid extraction.
"InMed''s innovative process targets significant cost savings as well as enhanced production, purification and quality control compared to existing grow-harvest-extract-purify methods employed by other companies. With similar scientific approaches used in multiple pharmaceutical applications, InMed''s biosynthesis system will allow the extraction of all of the 90+ naturally occurring cannabinoids. InMed''s proprietary biopharmaceutical approach to the production of pharmaceutical grade, bio-identical cannabinoids is a transformative technology in the rapidly emerging cannabinoid pharmaceutical, nutraceutical and medicinal sectors.
"On the cusp of revolutionizing cannabinoid extraction, InMed is assembling the world''s leading experts to assist with advancing its biosynthesis technology toward commercialization. In September, InMed retained Ben Paterson, P.E. as a consultant to help define the pathway for the scale-up, purification, and manufacturing strategies for InMed''s cannabinoid biosynthesis program ()."
InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed''s proprietary bioinformatics database assessment tool, the biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the company.
For more information, visit .
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today''s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company''s SEC filings. These risks and uncertainties could cause the company''s actual results to differ materially from those indicated in the forward-looking statements.
NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 01.11.2017 - 07:30 Uhr
Sprache: Deutsch
News-ID 1526778
Anzahl Zeichen: 4890
contact information:
Contact person:
Town:
NEW YORK, NY
Phone:
Kategorie:
Alternative
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 334 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"NetworkNewsWire Announces Publication Discussing Companies Developing Novel Methods of Extracting Medicinal-Grade Cannabinoids
"
steht unter der journalistisch-redaktionellen Verantwortung von
NetworkNewsWire (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
